Radiolabel studies suggest small peptides like exenatide and lixisenatide cross the BBB, while acylated or PEGylated analogues (liraglutide, semaglutide, NLY01) show minimal uptake
In this regard, GH has been used only to a limited extent in the treatment of patients with T2DM
The already massive GLP-1 obesity drug segment might have gained a major future competitor last week, following Roches acquisition of weight loss biotech Carmot Therapeutics
Dysmenorrhea, painful intercourse, painful bowel movements, bloating (often called "endo belly"), fatigue, and depression and anxiety are all part of the picture
A recent meta-analysis and epidemiological studies have shown that affected individuals can have an increased risk of developing diabetes and CVD [2, 4]
[1] Most cases are initially observed as an endocrine disorder in children that occurs equally in males and females, although males are often diagnosed more frequently